애드바이오텍, 엑시큐어와 다중 적응증 병용요법 공동개발 추진

The collaboration between Adbiotech and Exicure leverages an established Phase 2 asset, Burixafor, to explore high-potential combination therapies for complex indications like Sickle Cell Disease and Acute Myeloid Leukemia. This partnership signifies a strategic shift toward data-driven, multi-indication development, potentially accelerating the path to clinical validation and commercialization in the global hematology-oncology market.